Oral treatment

Oral Administration

Oral appliances

Oral Contraceptives

Oral and Pharyngeal Disorders

FDA Nod for Nymalize Nimodipine Oral Solution in SAH

The FDA has approved the first oral solution of nimodipine, with the aim of reducing fatal medication errors in patients with subarachnoid hemorrhage. FDA Approvals

EffRx announces US launch of new buffered oral solution for osteoporosis treatment

EffRx Pharmaceuticals has launched a new effervescent buffered oral solution (70mg), designed for the treatment of osteoporosis, in the US.

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

Arbor Pharma gains FDA nod for 1st nimodipine oral solution

The FDA on 14 May revealed it had approved Atlanta-based Arbor Pharmaceuticals' Nymalize, the first nimodipine oral solution to treat patients experiencing symptoms resulting from subarachnoid hemorr...

New nimodipine oral solution receives FDA approval for subarachnoid hemorrhage treatment

On May 10, the U.S. Food and Drug Administration approved Nymalize, a new nimodipine oral solution, to treat patients experiencing symptoms resulting from ruptured blood vessels in the brain (subarach...

FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved its New Drug Application for Nymalize (nimodipine) oral solution.

Mission Introduces Oral Solution

For years, physicians have prescribed Prednisolone (pred NIS oh lone) in a 15 mg/5 mL standard as a rescue medicine to treat severe asthma attacks, especially in children. Unfortunately, its taste has...

FDA approves Nymalize--first nimodipine oral solution for use in certain brain hemorrhage patients

On May 10, the U.S. Food and Drug Administration approved Nymalize, a new nimodipine oral solution, to treat patients experiencing symptoms resulting from ruptured blood vessels in the brain (subarach...

Effect of food on the bioavailability of lesogaberan given as an oral solution or as modified-release capsules in healthy male volunteers.

The novel Type B gamma-aminobutyric acid (GABAB)-receptor agonist lesogaberan (AZD3355) has been evaluated as an add-on to proton pump inhibitor treatment for gastroesophageal reflux disease, but the...

Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study.

Objective: To determine the oral bioavailability of a pregabalin capsule relative to a pregabalin solution. Methods: This was an open-label, randomized, crossover study in 12 healthy volunteers. Pharm...

Nebulization of mycophenolate mofetil inhalation suspension in rats: Comparison with oral and pulmonary administration of Cellcept(®).

In this study, a suspension of mycophenolate mofetil (MMF) suitable for inhalation was developed using the emulsion template process and characterized for particle size and aerosolization performance....

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

For use in chronic oral chemotherapeutic regimens, the potent anticancer drug docetaxel needs a solid oral dosage form. Because docetaxel has a very low permeability and a very low aqueous solubility...

Oral care practices of intensive care nurses: A descriptive study.

The aim of this study was to investigate intensive care unit (ICU) nurses' views and practices on oral care and to define the factors related to oral care measures. A study was carried out in eight IC...